PatenSee

Company Overview

Snapshot

Founded in March 2019 by Gal Goshen, Oz Seadia, and Hagay Drori, PatenSee operates with 11–50 employees. The company has raised $2.35M across two funding rounds from four investors. In September 2025, PatenSee received FDA Breakthrough Device Designation for its non-contact vascular access management system.

Business overview

PatenSee is a clinical-stage medical device company focused on developing a contactless surveillance system for the early detection of asymptomatic vascular stenosis in hemodialysis patients. The company leverages advanced multimodal imaging technologies and machine learning to identify stenosis risk at its earliest stages, enabling timely interventions to protect patient hemodialysis lifelines. PatenSee operates within the Health Tech & Life Sciences sector, specifically targeting the medical devices and digital healthcare markets.

Strategic signal

In September 2025, PatenSee received FDA Breakthrough Device Designation for its non-contact vascular access management system. This designation is a significant validation of the company's technology, signaling to investors and the industry a clear path toward accelerated regulatory review and potential market entry for a solution addressing a critical unmet need in dialysis patient care.

Company Intelligence Q&A

What is PatenSee's primary focus?

PatenSee is a clinical-stage medical device company developing a contactless surveillance system to detect early asymptomatic vascular stenosis in hemodialysis patients.

When was PatenSee founded and by whom?

PatenSee was founded in March 2019 by Gal Goshen, Oz Seadia, and Hagay Drori.

What significant regulatory milestone did PatenSee achieve recently?

In September 2025, PatenSee received FDA Breakthrough Device Designation for its non-contact vascular access management system for patients undergoing hemodialysis.

What was a key partnership announced by PatenSee?

In February 2024, PatenSee signed a clinical collaboration agreement with Fresenius Medical Care.

When did PatenSee initiate its first in-human trial?

PatenSee initiated its first in-human trial with its contactless imaging surveillance system for patients undergoing hemodialysis in February 2021.